✉ Email this page to a colleague
« Back to Dashboard
Ganaxolone is an investigational drug.
There have been 21 clinical trials for Ganaxolone. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2015.
The most common disease conditions in clinical trials are Epilepsy, Depression, and Disease. The leading clinical trial sponsors are Marinus Pharmaceuticals, U.S. Army Medical Research and Development Command, and U.S. Army Medical Research and Materiel Command.
There are one hundred and twenty-nine US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Ganaxolone
|Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old||Marinus Pharmaceuticals||Phase 3|
|Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy||Marinus Pharmaceuticals||Phase 3|
|RAndomized Therapy In Status Epilepticus||Marinus Pharmaceuticals||Phase 3|
Top disease conditions for Ganaxolone
Top clinical trial sponsors for Ganaxolone
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ganaxolone||See Plans and Pricing||Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties||RESEARCH TRIANGLE INSTITUTE (Research Triangle Park, NC) THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Washington, DC)||See Plans and Pricing|
|Ganaxolone||See Plans and Pricing||Uses of ganaxolone||WISCONSIN ALUMNI RESEARCH FOUNDATION (Madison, WI)||See Plans and Pricing|
|Ganaxolone||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Ganaxolone||See Plans and Pricing||Sugar ester nanoparticle stabilizers||St. John's University (Queens, NY)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Ganaxolone||Australia||AU2008265898||2027-06-15||See Plans and Pricing|
|Ganaxolone||Canada||CA2698172||2027-06-15||See Plans and Pricing|
|Ganaxolone||European Patent Office||EP2155204||2027-06-15||See Plans and Pricing|
|Ganaxolone||Spain||ES2589139||2027-06-15||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|